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ConCise report
A rare coding allele in IFIH1 is protective for 
psoriatic arthritis
Ashley Budu-Aggrey,1,2 John Bowes,1 philip e stuart,3 Matthew Zawistowski,4 
Lam C tsoi,3,4 rajan nair,3 Deepak rohit Jadon,5,6 neil McHugh,5,7 
eleanor Korendowych,5 James t elder,3,8 Anne Barton,1,2 soumya raychaudhuri1,2,9,10
ABstrAct
Objectives psoriatic arthritis (psA) is an inflammatory 
arthritis associated with psoriasis. While many common 
risk alleles have been reported for association with psA 
as well as psoriasis, few rare coding alleles have yet been 
identified.
Methods to identify rare coding variation associated 
with psA risk or protection, we genotyped 41 267 
variants with the exome chip and investigated 
association within an initial cohort of 1980 psA cases 
and 5913 controls. Genotype data for an independent 
cohort of 2234 psA cases and 5708 controls was also 
made available, allowing for a meta-analysis to be 
performed with the discovery dataset.
results We identified an association with the rare 
variant rs35667974 (p=2.39x10−6, or=0.47), encoding 
an ile923Val amino acid change in the IFIH1 gene 
protein product. the association was reproduced in 
our independent cohort, which reached a high level of 
significance on meta-analysis with the discovery and 
replication datasets (p=4.67x10−10). We identified a 
strong association with IFIH1 when performing multiple-
variant analysis (p=6.77x10−6), and found evidence of 
independent effects between the rare allele and the 
common psA variant at the same locus.
conclusion For the first time, we report a rare coding 
allele in IFIH1 to be protective for psA. this rare allele has 
also been identified to have the same direction of effect 
on type i diabetes and psoriasis. While this association 
further supports existing evidence for IFIH1 as a causal 
gene for psA, mechanistic studies will need to be 
pursued to confirm that IFIH1 is indeed causal.
IntrOductIOn
In approximately 6%–42% of cases psoriasis is 
associated with an inflammatory arthritis,1 psoriatic 
arthritis (PsA), which includes joint inflammation, 
involving primarily the distal interphalangeal (DIP) 
joints, entheses and sacroiliac joints. As patients 
typically test negative for rheumatoid factor, PsA 
is considered one of the spondyloarthropathies.1 
Patients with PsA have a worse quality of life than 
patients with psoriatic skin disease alone.2 PsA may 
demonstrate a greater genetic component than 
psoriasis; a recent family study among first-degree 
relatives estimated a sibling recurrence risk (λs) 
between 30 and 40, greater than that of psoriasis, 
where the recurrence risk is between 4 and 10.3 4
Genome-wide association studies have identi-
fied common risk alleles that are associated with 
both psoriasis and PsA.5–10 Familial studies11 and 
case-control studies12 have reported rare missense 
alleles in CARD14 that confer strong risk of psori-
asis, but to date no rare coding alleles have been 
identified for PsA risk. As rare coding variants are 
more likely to result in an interpretable functional 
effect, they might more easily provide insight into 
the mechanism of disease than known common 
variants associated with psoriasis and PsA. If rare 
alleles are protective, have a strong effect and result 
in loss of gene function, they could be flagging 
promising drug targets.13 For example, the Y142X, 
C679X and R46L alleles in PCSK9 identified this 
gene as a promising drug target for lipid modifica-
tion.14 15
To identify rare alleles that are associated with PsA 
(MAF<0.05), we queried the exome by analysing 
1980 PsA cases and 5913 healthy controls that 
were genotyped using the Illumina HumanExome 
chip and HumanCoreExome chip. In doing so, we 
report an association with a rare coding variant at 
the IFIH1 locus.
MethOds
study sample description
We recruited a total of 2384 patients with PsA and 
5946 healthy individuals in this study following 
approval of the research ethics committee (MRES 
99/8/84), as described previously.16 All participants 
were the UK Caucasians and had provided written 
informed consent.
Genotyping
We genotyped DNA samples using the Infinium 
HumanExome-12 BeadChip (V.1-0) (Illumina) 
and the Infinium HumanCoreExome-24 Bead-
Chip (V.1-0) (Illumina) (see online supplementary 
table 1), where 691 cases and all control samples 
were genotyped with the HumanExome chip, and 
the remaining 1693 cases were genotyped with 
the HumanCoreExome chip within the Arthritis 
Research UK Centre for Genetics and Genomics at 
The University of Manchester.
Genotype calling and quality control
We performed genotype calling and clustering with 
the GenomeStudio Data Analysis software (Geno-
typing Module V.1.8.4). We carried out initial geno-
type clustering to identify and exclude samples with 
a genotyping call rate <98%. We then performed 
automated reclustering of the remaining samples to 
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obtain more accurate genotype clusters. As we were concerned 
that rare variants may be incorrectly clustered, we conducted an 
extensive manual review of clusters. We reviewed variants that 
were filtered based on cluster separation (<0.4), signal intensity 
(<1.0) and allele frequency, where we identified variants that 
had failed genotyping, and those that had been incorrectly called 
as ‘missing’.
statistical quality control
We identified duplicated samples and related individuals using 
identity-by-descent with PLINK software (see online supplemen-
tary table 2). We also performed principal component analysis 
with the EIGENSOFT software package (V.6.0.1), to identify 
and exclude samples with divergent ancestry (see online supple-
mentary figure 1, supplementary table 2). Principal components 
were calculated with a set of linkage disequilibrium (LD)-pruned 
single nucleotide polymorphisms (SNPs) (n=13 444). We 
excluded monomorphic, Y chromosome, pseudoautosomal, 
mitochondrial and variants within the human leukocyte antigen 
(HLA) region, as well as variants with a call rate <100% in 
order to ensure high quality of the data. We also excluded SNPs 
found to significantly deviate from Hardy-Weinberg equilibrium 
(<1.0×10−6) among the control samples.
To prevent any bias due to differences in genotyping between 
the two platforms used in this study, we excluded all variants 
with evidence of case allele frequency differences between the 
two platforms (p<0.05) (see online supplementary figure 2). We 
also excluded variants with an allele count of 0 among either 
of the case cohorts or the control samples. Furthermore, we 
excluded rare variants showing evidence of genotyping bias by 
assessing the allele counts of cases and controls for each geno-
typing platform used.
replication dataset
We used an independent cohort of 2234 PsA cases and 5708 
controls to replicate our findings. Briefly, people of European 
Caucasian ancestry were collected in North America and Sweden, 
and were genotyped using the Affymetrix Axiom Biobank Plus 
Genotyping Array. More details of this cohort, as well as quality 
control procedures applied to the genotype data, have been 
described previously.17
Association testing
We performed single-point analysis using the Fisher's exact test 
in PLINK with all SNPs passing quality control, and separately 
for rare variants. We calculated genomic inflation for all vari-
ants, and separately for rare and common variants alone, where 
we created a null SNP set (n=13 106) with the common vari-
ants and excluded previously reported psoriasis loci (see online 
supplementary figures 3–5). We performed multiple-variant 
testing with the rare variants using SKAT analysis in R. We used 
the Firth logistic regression test (with four principal components 
as covariates) for association analysis of the replication cohort. 
In our replication cohort, principal components had been calcu-
lated with a set of LD-pruned SNPs, where known psoriasis loci 
had been excluded (n=11 005). We performed a meta-analysis 
with the discovery and independent cohort data assuming an 
inverse-variance fixed-effects model. The choice of methods to 
perform the single-variant analysis was based on their suitability 
for analysing rare variants.
IFIH1 conditional analysis and conditional haplotype analysis
At the IFIH1 locus, we performed conditional logistic regression 
in PLINK to test for independence between the rare (Ile923Val) 
and common (rs984971) variants using PsA Immunochip geno-
type data (1962 cases, 8923 controls). We also used this dataset 
to construct haplotypes in PLINK to test for association with 
PsA, where we calculated OR and 95% CIs. We performed 
conditional haplotype analysis based on a likelihood ratio, to test 
for an effect of Ile923Val independent from that of rs984971.
results
After quality control, we examined genotype data for 41 267 
non-HLA variants in 1980 cases and 5913 controls (see online 
supplementary table 3). We excluded more case samples compared 
with controls due to the overlap of case samples that were geno-
typed on both platforms. We carried out single-point analysis using 
the Fisher's exact test to identify associations with PsA. Unsur-
prisingly, we observed evidence of association in our cohort at 
known PsA alleles (see online supplementary table 4), including the 
rs33980500 SNP at TRAF3IP2 (p=3.9×10−18). After removing 
these known associations, we observed only modest genomic infla-
tion (λ=1.06, λ1000,1000=1.02), suggesting little evidence of popula-
tion stratification (see online supplementary figure 4).
We conducted a single-point analysis for a total of 27 066 rare 
variants alone (MAF<0.05, λ=0.79) (see online supplementary 
figure 5). The strongest association we found was with the SNP 
rs35667974 (p=2.39×10−6, OR=0.47) (see online supplemen-
tary figures 6 and 7, supplementary table 5), mapping to IFIH1; 
this variant causes a missense mutation, resulting in an amino 
acid substitution of valine for isoleucine (Ile923Val). Of the 18 
variants taken forward for replication (p<1.0×10−3), we only 
found the Ile923Val association to replicate within our inde-
pendent cohort (p=3.5×10−5, OR=0.49), based on a Bonfer-
roni-corrected p value threshold of 2.78×10–3 (=0.05/18, see 
online supplementary tables 6 and 7). On meta-analysis with 
the discovery and replication datasets, we found the association 
with the Ile923Val allele to exceed genome-wide significance 
(p=4.78×10-10). We performed multiple-variant analysis to 
assess allele counts among genes and obtained further evidence 
to support the association of IFIH1 with PsA (p=6.77×10−6, 
Bonferroni-corrected p value threshold=5.60×10−6, based on 
the number of genes tested) (see online supplementary table 8).
Independent effects at the IFIH1 locus
A common variant at IFIH1 has been previously reported as 
associated with PsA in our recent Immunochip study.9 When 
performing single-point analysis with the Immunochip dataset, 
we found evidence for an independent signal within the locus. In 
that study, we observed that Ile923Val obtained nominal signifi-
cance after conditional analysis (figure 1). We also observed this 
association to be stronger than that previously reported for the 
common variant at the same locus, rs984971 (p=3.62×10−6). 
When we performed conditional logistic regression, the 
Ile923Val variant remained associated with PsA (p<0.05) while 
conditioning on rs984971 (pcond=4.0×10
−6) (figure 1). Like-
wise, the SNP rs984971 remained associated with PsA when 
we conditioned on the Ile923Val variant (pcond=1.6×10
−4) 
(figure 1). This gives evidence of the independent effects of the 
two variants. We performed conditional haplotype analysis using 
haplotypes constructed with both variants (figure 2). Here, we 
found that the derived haplotype containing Ile923Val (CG) 
has a significantly greater protective effect compared with that 
containing the derived allele at rs984971 (TA), relative to the 
ancestral haplotype (TG) (p=6.36×10−11 vs pcond=2.95×10
−7). 
This confirms that the association with the rare IFIH1 variant is 
not driven by the common rs984971 variant.
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dIscussIOn
We have identified a PsA association with the rare coding allele 
Ile923Val within the IFIH1 gene. This rare allele was found to 
be protective for PsA, and also replicated within an independent 
cohort. We found the association signal to reach genome-wide 
significance during meta-analysis, and confirmed the associa-
tion with IFIH1 when performing multiple-variant analysis. The 
Ile923Val allele has been previously reported to be protective for 
type 1 diabetes18 and psoriasis.19 Associations within the IFIH1 
locus have also been reported to increase PsA risk.10 20 However, 
until now no association with the Ile923Val allele has been 
reported to have a protective effect on PsA alone. We found the 
Ile923Val variant to be independent of the common SNP previ-
ously identified at the IFIH1 locus (rs984971). This SNP is highly 
correlated (r2=0.64) with an additional common IFIH1 variant 
(rs1990760) that has been recently reported for PsA.10 We also 
found the Ile923Val variant to have an independent effect from 
this variant (Pcond=4.39×10
−6). Furthermore, we also found the 
Ile923Val variant to be independent of the common rs3747517 
IFIH1 variant previously reported for PsA (Pcond=7.73×10
−7).10 
These findings highlight the relevance of IFIH1 in immune-related 
disorders, especially given the recent association reported for the 
rare IFIH1 allele with ankylosing spondylitis, Crohn's disease, 
psoriasis, primary sclerosing cholangitis and ulcerative colitis.21 
The frequency of the Ile923Val variant in our control population 
(0.021) is slightly higher than observed in European populations 
in the 1000 genomes project and the exome sequencing project 
(0.01–0.018).22 23 This should be taken into consideration when 
interpreting the results of this study.
As the rare allele identified lies within a coding region, this 
provides strong evidence to suggest that IFIH1 is a causal gene 
for PsA. As discussed by Plenge et al,13 a rare and independent 
variant in a causal gene for disease could provide a potential 
therapeutic target for treatment. However, linking human 
genetics with therapeutic targets requires the biological function 
of the causal gene and variant to be known.
IFIH1 encodes a cytoplasmic RNA helicase that recognises 
viral RNA and mediates an immune response on viral infection.18 
The protective effect of the rare IFIH1 allele observed with PsA 
suggests that the variant results in a loss of function phenotype, 
where the production or activity of IFIH1 is decreased. Increased 
expression levels of IFIH1 have been observed in psoriasis skin 
lesions compared with healthy skin,10 suggesting that pharmaco-
logical inhibition of this gene could be effective in treating psori-
atic disease. However, when investigating the effect of Ile923Val 
in knockout mice, mutants showed no change in their double-
stranded RNA binding activity compared with the wild-type.24 
This indicates the requirement for further investigation into the 
biological effect before any conclusions can be drawn from our 
current study regarding the impact of this allele on disease or the 
potential for treatment of PsA. Mechanistic studies will also be 
required to confirm that IFIH1 is causal for PsA.
In conclusion, we report for the first time an association with 
a rare coding allele in IFIH1 that is protective for PsA, and 
independent of associations that have previously been reported 
within this locus.
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